Cargando…
2815. Outcomes of Novel Antimicrobials Compared to Polymyxin B for treatment of infections due Carbapenem-Resistant Enterobacterales Infections
BACKGROUND: Carbapenem-resistant Gram-negative infections remain a serious threat due to their increasing incidence and high mortality rates. Since 2015, various antimicrobials with in vitro activity against carbapenem-resistant Enterobacterales (CRE) have been approved for use. There is limited evi...
Autores principales: | Zheng, Tina, Kubin, Christine J, Nelson, Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677926/ http://dx.doi.org/10.1093/ofid/ofad500.2426 |
Ejemplares similares
-
2262. Ceftazidime–Avibactam vs. Polymyxin B in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
por: John, Jamie, et al.
Publicado: (2019) -
1029. Increased Mortality in Hospital-Onset Carbapenem-Resistant Enterobacterales Bloodstream Infections
por: Boutzoukas, Angelique E, et al.
Publicado: (2023) -
2477. Characteristics of patients infected with Carbapenem-resistant Acinetobacter baumannii complex and Carbapenem-resistant Enterobacterales in Tennessee, 2016–2021
por: Patel, Dipen, et al.
Publicado: (2023) -
1190. Reduction of Carbapenem-Resistant Enterobacteria (CRE) Infections and Total Polymyxin B Use Due to a Comprehensive Infection Control Strategy in Colombia
por: Velez, Juan Diego, et al.
Publicado: (2018) -
716. Effect of Carbapenem-resistant vs. Carbapenem-susceptible Enterobacterales infections on patient outcomes at an academic medical center
por: Clark, Justin A, et al.
Publicado: (2023)